がん疼痛管理市場：薬剤タイプ、投与経路、用途、最終用途別-2025～2030年の世界予測

がん疼痛管理市場は、2023年に74億2,000万米ドルと評価され、2024年には78億6,000万米ドルに達すると予測され、CAGR 6.09％で成長し、2030年には112億3,000万米ドルに達すると予測されています。

がん疼痛管理産業は、がん患者の痛みを和らげることを目的とした幅広い治療と技術を包含しています。この範囲には、オピオイド、非ステロイド性抗炎症薬、補助療法などの薬理学的治療に加え、鍼治療、理学療法、神経調節などの非薬理学的方法が含まれます。がん疼痛管理の必要性は、疾患やその治療に伴い、患者のQOLに影響を与える、しばしば衰弱させるような激しい痛みから生じる。疼痛管理オプションの応用は緩和ケアにとどまらず、様々ながん治療の段階を通じて患者に生活の質や機能的能力の向上を記載しています。最終用途の範囲は広く、病院、外来手術センター、専門クリニック、在宅ケア環境などが含まれます。市場の成長は、がん罹患率の上昇、疼痛管理技術の進歩、QOL向上に対する患者の意識と需要の高まりに大きく影響されています。

主要成長要因としては、より正確で効果的な疼痛緩和を目指した技術の進歩や新しい治療の開発、政府の好意的な取り組みや医療インフラへの投資などが挙げられます。効果的な疼痛管理へのアクセスが改善し、統合的な疼痛管理アプローチの採用が増加している新興市場に潜在的なビジネス機会があります。こうした機会を捉えるための調査には、革新的な研究への投資や、包括的な疼痛管理ソリューションのための医療プロバイダーとのパートナーシップの拡大が含まれます。しかし、この市場は、規制上の課題、先進的治療に伴う高コスト、オピオイドベースの管理戦略を制限するオピオイド危機などの限界に直面しています。また、中低所得国におけるアクセスの障壁や、個別化された疼痛管理ソリューションの実現が複雑であることも課題となっています。

イノベーションと調査は、個別化医療、非オピオイド代替薬、心理的サポートを統合したホリスティック・アプローチを優先すべきです。これらのセグメントに注力することで、企業は事業の成長と市場での差別化を高めることができます。市場の性質はダイナミックで集学的であり、包括的ながん治療戦略への継続的な適応と新たな洞察の統合が求められます。がん疼痛管理市場の利害関係者は、進化する患者のニーズや規制の枠組みに合わせることで、この重要な医療セグメントにおける多様な課題や機会に効果的に対処することができます。

市場力学：急速に進化するがん疼痛管理市場の主要市場洞察を公開

がん疼痛管理市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疼痛と生活習慣病の有病率の上昇
  • 高齢者の増加と疼痛緩和療法へのニーズ
• 市場抑制要因
  • 製品回収に関する問題
• 市場機会
  • 継続的な製品開発活動とFDAによる新製品承認の増加
  • がん性疼痛治療を支援する政府の資金援助
• 市場課題
  • がん疼痛管理医薬品に関連する副作用

ポーターのファイブフォース：がん疼痛管理市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん疼痛管理市場における外部からの影響の把握

外部マクロ環境要因は、がん疼痛管理市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：がん疼痛管理市場における競合情勢の把握

がん疼痛管理市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：がん疼痛管理市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん疼痛管理市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：がん疼痛管理市場における成功への道筋を描く

がん疼痛管理市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疼痛と生活習慣病の罹患率が世界中で上昇
    • 高齢者の増加と痛みを軽減する治療法の必要性
  • 抑制要因
    • 製品リコールに関連する問題
  • 機会
    • 継続的な製品開発活動と新製品のFDA承認の増加
    • がんの痛みの治療を支援する政府の資金援助
  • 課題
    • がん疼痛管理薬剤に関連する副作用
• 市場セグメンテーション分析
  • 薬剤タイプ：がんの痛みの治療におけるオピオイドの適用範囲の拡大
  • 投与経路：がん疼痛管理の経口薬の利用可能性が高まっている
  • 用途：乳がんに対するがん疼痛管理ソリューションの普及
  • 最終用途：病院におけるがん鎮痛薬の使用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 がん疼痛管理市場：薬剤タイプ別

• イントロダクション
• 神経遮断薬
• 非オピオイド
  • アセトアミノフェン
  • 非ステロイド性抗炎症薬（NSAID）
• オピオイド
  • フェンタニル
  • モルヒネ

第7章 がん疼痛管理市場：投与経路別

• イントロダクション
• 経口
• 母子

第8章 がん疼痛管理市場：用途別

• イントロダクション
• 血液がん
• 乳がん
• 大腸がん
• 肺がん
• 前立腺がん

第9章 がん疼痛管理市場：最終用途別

• イントロダクション
• 在宅医療
• 病院
• 専門クリニック

第10章 南北アメリカのがん疼痛管理市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋のがん疼痛管理市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのがん疼痛管理市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • FDA、軽度から中等度の痛みに非オピオイド鎮痛剤を承認
  • 慢性疼痛治療をカスタマイズするNevro（NVRO）の最新リリース
  • EsteveとMedtronicががん疼痛患者のニーズに応えるために協力
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Aegis Therapeutics, LLC
• Aptinyx Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Baxter International Inc.
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Eisai Co., Ltd.
• Eli Lilly and Company
• Glaxosmithkline PLC
• Grunenthal Group
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Scilex Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Trevena Inc.

LIST OF FIGURES

• FIGURE 1. CANCER PAIN MANAGEMENT MARKET RESEARCH PROCESS
• FIGURE 2. CANCER PAIN MANAGEMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER PAIN MANAGEMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER PAIN MANAGEMENT MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NERVE BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 51. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 52. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 83. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 84. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 89. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 90. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 190. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 192. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 193. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 214. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 215. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 216. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 217. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 220. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 221. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 222. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 223. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 280. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 281. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Pain Management Market was valued at USD 7.42 billion in 2023, expected to reach USD 7.86 billion in 2024, and is projected to grow at a CAGR of 6.09%, to USD 11.23 billion by 2030.

The Cancer Pain Management industry encompasses a wide range of treatments and technologies aimed at alleviating pain in individuals with cancer. This scope includes pharmacological treatments such as opioids, NSAIDs, and adjuvant therapies, along with non-pharmacological methods like acupuncture, physiotherapy, and neuromodulation. The necessity for cancer pain management arises from the severe, often debilitating pain that can accompany the disease and its treatments, impacting patients' quality of life. The application of pain management options extends beyond palliative care, offering enhanced life quality and functional capabilities for patients throughout various cancer treatment stages. End-use scopes are broad, including hospitals, ambulatory surgical centers, specialty clinics, and home care settings. Market growth is heavily influenced by the rising prevalence of cancer, advancements in pain management technologies, and increasing patient awareness and demand for quality of life improvements.

Key growth factors include technological advancements and the development of new therapeutics aimed at more precise and effective pain relief, along with favorable government initiatives and investments in healthcare infrastructure. Potential opportunities lie in emerging markets where access to effective pain management is improving and the adoption of integrative pain management approaches is increasing. Recommendations to capture these opportunities involve investing in innovative research and expanding partnerships with healthcare providers for comprehensive pain management solutions. However, the market faces limitations including regulatory challenges, high costs associated with advanced therapies, and the opioid crisis, which limits opioid-based management strategies. Challenges also stem from barriers to access in low and middle-income countries and the complexity of achieving personalized pain management solutions.

Innovation and research should prioritize personalized medicine, non-opioid alternatives, and holistic approaches integrating psychological support. By focusing on these areas, companies can enhance business growth and market differentiation. The nature of the market is dynamic and multidisciplinary, requiring continuous adaptation and integration of novel insights into comprehensive cancer care strategies. By aligning with evolving patient needs and regulatory frameworks, stakeholders in the cancer pain management market can effectively address the diverse challenges and opportunities within this critical healthcare segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Pain Management Market

The Cancer Pain Management Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic pain and lifestyle disorders worldwide
  • Increasing geriatric population and need for pain-reducing therapies
• Market Restraints
  • Issues associated with product recalls
• Market Opportunities
  • Ongoing product development activities and rising FDA approvals of new products
  • Government funding supporting cancer pain treatments
• Market Challenges
  • Adverse effects associated with cancer pain management drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Pain Management Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Pain Management Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Pain Management Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Pain Management Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Pain Management Market

A detailed market share analysis in the Cancer Pain Management Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Pain Management Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Pain Management Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Pain Management Market

A strategic analysis of the Cancer Pain Management Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Pain Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aegis Therapeutics, LLC, Aptinyx Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Glaxosmithkline PLC, Grunenthal Group, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Trevena Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Pain Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Nerve Blockers, Non-Opioids, and Opioids. The Non-Opioids is further studied across Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The Opioids is further studied across Fentanyl and Morphine.
• Based on Route of Administration, market is studied across Oral and Parental.
• Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
• Based on End-Use, market is studied across Home care, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic pain and lifestyle disorders worldwide
    • 5.1.1.2. Increasing geriatric population and need for pain-reducing therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing product development activities and rising FDA approvals of new products
    • 5.1.3.2. Government funding supporting cancer pain treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with cancer pain management drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing applicability of opioids to treat cancer pain
  • 5.2.2. Route of Administration: Growing availability of oral medications for cancer pain management
  • 5.2.3. Application: Emerging penetration of cancer pain management solutions for breast cancer
  • 5.2.4. End-Use: Elevating usage of cancer pain drugs in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Pain Management Market, by Drug Type

• 6.1. Introduction
• 6.2. Nerve Blockers
• 6.3. Non-Opioids
  • 6.3.1. Acetaminophen
  • 6.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.4. Opioids
  • 6.4.1. Fentanyl
  • 6.4.2. Morphine

7. Cancer Pain Management Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parental

8. Cancer Pain Management Market, by Application

• 8.1. Introduction
• 8.2. Blood Cancer
• 8.3. Breast Cancer
• 8.4. Colorectal Cancer
• 8.5. Lung Cancer
• 8.6. Prostate Cancer

9. Cancer Pain Management Market, by End-Use

• 9.1. Introduction
• 9.2. Home care
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Americas Cancer Pain Management Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cancer Pain Management Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Pain Management Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FDA Approves Non-Opioid Painkiller for Mild-to-Moderate Pain
  • 13.3.2. Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
  • 13.3.3. Esteve and Medtronic are Collaborating to Address Cancer Pain Patients' Needs
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Aegis Therapeutics, LLC
• 4. Aptinyx Inc.
• 5. Astellas Pharma Inc.
• 6. Bausch Health Companies Inc.
• 7. Baxter International Inc.
• 8. Bayer AG
• 9. Biogen Inc.
• 10. Boehringer Ingelheim International GmbH
• 11. Eisai Co., Ltd.
• 12. Eli Lilly and Company
• 13. Glaxosmithkline PLC
• 14. Grunenthal Group
• 15. Johnson & Johnson Services, Inc.
• 16. Merck & Co. Inc.
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Regeneron Pharmaceuticals Inc.
• 20. Sanofi SA
• 21. Scilex Pharmaceuticals
• 22. Teva Pharmaceutical Industries Ltd.
• 23. Trevena Inc.